Skip to main content

This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.

This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.

Adverse events reporting information can be found in the footer of this page.

Novartis Pro Portal

Main navigation

    Menu
  • Medicines
    • Cardio-metabolic
      • ENTRESTO (sacubitril/valsartan)
      • LEQVIO®▼ (inclisiran)
    • Dermatology
      • COSENTYX® (secukinumab)
      • XOLAIR® (omalizumab)
    • Haematology
      • FABHALTA®▼ (iptacopan)
      • SCEMBLIX®▼ (asciminib)
    • Immunology
      • ILARIS® (canakinumab)
    • Neuroscience
      • AIMOVIG® (erenumab)
      • KESIMPTA®▼ (ofatumumab)
    • Oncology
      • KISQALI® (ribociclib)
      • TAFINLAR (dabrafenib) + MEKINIST (trametinib) in non-small cell lung cancer (NSCLC)
      • TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in melanoma
      • SANDOSTATIN® LAR® (octreotide acetate)
    • Radioligand therapy (RLT)
      • Pluvicto®▼ (lutetium [177Lu] 
vipivotide tetraxetan)
    • Respiratory and Inflammation
      • XOLAIR® (omalizumab)
    • Rheumatology
      • COSENTYX® (secukinumab)
  • Therapy Areas
    • Cardio-metabolic
    • Dermatology
    • Haematology
    • Immunology
    • Neuroscience
    • Oncology
    • Radioligand therapy (RLT)
    • Respiratory and inflammation
    • Rheumatology
  • Events
  • Resources
  • Healthcare Systems Support
    • Disease area service resources
      • Service resources: Oncology
      • Breast Cancer Inequalities Tool
    • Collaborative Working
    • Contact us
Login
All Filters
Therapeutic Area
Therapeutic Area
Format
What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Format
top

Therapy Areas

  • Print
  • PDF
Understanding prostate cancer. The burden of prostate cancer and how the disease progresses.

Article
3 mins

Understanding prostate cancer

Article
- 05 Sep 2025
3 mins

Understanding prostate cancer

See more details
Hide details
Scanning for PSMA. Understanding PSMA as a diagnositc biomarker for prostate cancer.

Article
3 mins

Scanning for PSMA

Article
- 05 Sep 2025
3 mins

Scanning for PSMA

See more details
Hide details
Neuroendocrine tumour preview image.

Article
1 min

Background to neuroendocrine tumours

Article
- 27 Aug 2025
1 min

Background to neuroendocrine tumours

See more details
Hide details
  • Print
  • PDF

Novartis Pharmaceuticals UK Limited is a limited liability company registered in England and Wales under number 119006.


Registered office: The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ.

UK | July 2025 | FA-11207513-3
 

Explore the Site
  • Medicines
  • Therapy areas
  • Events
  • Resources
  • Healthcare Systems Support
Helpful Links
  • Privacy Notice
  • Terms of Use
  • Accessibility
  • Contact us

© 2025 Novartis Pharmaceuticals UK Limited. All rights reserved.

people chatting in the office

Welcome to Pro.Novartis.com

The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.

*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.

This website is designed to be viewed on desktop.

I am a UK healthcare professional and/or an NHS professional involved in service or budgetary planning responsibilities
I am a member of the public
people chatting in the office

Welcome to Pro.Novartis.com

The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.

*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.

This website is designed to be viewed on desktop.

I am a UK healthcare professional and/or an NHS professional involved in service or budgetary planning responsibilities
I am a member of the public